Search Results
Biomarkers and patient eligibility for CAR T-cell therapies in DLBCL
Biomarkers and patient eligibility for CAR T cell therapies in MM
CAR T-cell case study: Sequencing therapies for patients with high-risk DLBCL
Choosing the right CAR-T therapy for R/R DLBCL
Sattva S. Neelapu, MD: Encouraging Results for CAR T-Cells in Refractory DLBCL
CAR T-cells in lymphoma: new advances and practical aspects
DLBCL: CAR-T as Curative Treatment/Bridge to Transplant
CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma
CAR T-Cell Therapy Role in DLBCL - Sameer Al-Amoudi (JED) - 11-12 Feb 2022
CAR-T in Lymphoma
Engineering T Cells for Cancer - Carl June
What's New in the Approach to DLBCL Upfront and in the Relapsed Setting Beyond CAR T
